A subset of patients with non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhibitor (ICI) therapy due ...

Dose escalation offers no survival benefits but increases grade ≥ 3 toxicity compared with standard radiation in patients ...

A majority of cases of diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma globally, are ...

Professor Park Joon-sik of obstetrics and gynecology at Soonchunhyang University Bucheon Hospital announced on the 14th that ...

Innovative polatuzumab vedotin plus R-CHP therapy reshapes treatment of older adult patients with diffuse large B-cell lymphoma.

Progression-free survival improvement and drug costs make zanubrutinib a more cost-effective option in relapsed or refractory ...

Researchers have demonstrated the potential of the innovative optical genome mapping (OGM) technique for the diagnosis, ...

The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) on Thursday authorized GSK plc’s (NYSE:GSK) Blenrep.

Updated phase 3 data support pembrolizumab plus concurrent chemoradiotherapy as a standard of care for patients with high-risk, locally advanced cervical cancer, according to Linda Duska, MD.

Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo.